New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:39 EDTLJPC, GALTGalectin drug showed no difference from placebo, The Street reports
Galectin's (GALT) GR-MD-02 showed no difference from placebo across most efficacy biomarkers in a phase I study of nonalcoholic steatohepatitis, The Street's Adam Feuerstein reports. The stock is trading down 50% today to $7.24 while La Jolla (LJPC), which is developing a similar drug to treat NASH, is down 13%. Reference Link
News For GALT;LJPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:58 EDTLJPCDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 15, 2015
09:56 EDTLJPCTang Capital increases stake in La Jolla Pharmaceutical to 15.3%
Subscribe for More Information
May 14, 2015
08:23 EDTGALTGalectin Therapeutics' fibrosis and cancer candidate passes FDA requirement
Subscribe for More Information
May 11, 2015
08:30 EDTGALTGalectin Therapeutics reports Q1 EPS (22c), one estimate (20c)

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use